GABAB receptors blockage modulates somatic and aversive manifestations induced by nicotine withdrawal - 17/06/21
pages | 15 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Abstract |
There is substantial evidence that GABAB agonist, baclofen, prevents somatic and motivational responses induced by nicotine withdrawal and may target drug cue vulnerabilities in humans. In this context, we explored different aspects associated with the possible mechanisms whereby the GABAB receptors might influence nicotine withdrawal. Male mice received nicotine (2.5 mg/kg, s.c.) 4 times daily, for 7 consecutive days. Nicotine-treated mice received the nicotinic acetylcholine receptor antagonist, mecamylamine (MEC, 2 or 3.5 mg/kg, s.c.), to precipitate the withdrawal state. A second group of dependent mice received 2-hydroxysaclofen (GABAB receptor antagonist, 1 mg/kg, s.c.) before MEC-precipitated abstinence. Somatic signs of nicotine withdrawal were measured for 30 min. Anxiogenic-like response associated to nicotine withdrawal was assessed by the elevated plus maze test. The dysphoric/aversive effect induced by nicotine withdrawal was evaluated using conditioned place aversion paradigm. Dopamine, serotonin and its metabolites concentrations were determined by HPLC in the striatum, cortex and hippocampus. Finally, α4β2 nicotinic acetylcholine receptor density was determined in several brain regions using autoradiography assays. The results showed that MEC-precipitated nicotine withdrawal induced somatic manifestations, anxiogenic-like response and dysphoric/aversive effect, and 2-hydroxysaclofen potentiated these behavioral responses. Additionally, 2-hydroxysaclofen was able to change striatal dopamine levels and α4β2 nicotinic acetylcholine receptor density, both altered by MEC-precipitated nicotine withdrawal. These findings provide important contributions to elucidate neurobiological mechanisms implicated in nicotine withdrawal. We suggest that GABAB receptor activity is necessary to control alterations induced by nicotine withdrawal, which supports the idea of targeting GABAB receptors to treat tobacco addiction in humans.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | 2-hydroxysaclofen potentiated somatic signs induced by nicotine withdrawal. |
• | 2-hydroxysaclofen potentiated anxiogenic-like response of nicotine withdrawal. |
• | 2-hydroxysaclofen potentiated dysphoric/aversive response of nicotine withdrawal. |
• | 2-hydroxysaclofen increased the neurochemical alterations of nicotine withdrawal. |
• | 2-hydroxysaclofen potentiated the increase in nAChRs induced by nicotine withdrawal. |
Abbreviations : NIC, SAL, VEH, MEC, GABA, SAC, BAC, DA, DOPAC, 5-HT, 5-HIAA, nAChR, HPLC, AcbC, AcbSh, CPu, BST, MHb, DLG, fr, VTA, Ip, SN, PAG, CNS
Keywords : GABAB receptor, 2-hydroxysaclofen, Nicotine, Withdrawal, Addiction, Mice
Plan
Vol 140
Article 111786- août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?